Markwell Clarizio LLP

August 2024

Rovi #2: Federal Court of Appeal Confirms Interactive Television Program Guide Patents Are Invalid (Rovi ats. Bell and Telus)

  On August 6, 2024, the Federal Court of Appeal (per Gleason JA; Stratas and Monaghan JJA, concurring) held that two patents owned by Rovi Guides [Rovi] were invalid. Nonetheless, in obiter, the FCA provided clarification on the circumstances in which an accounting of profits and a permanent injunction are available as remedies for patent […]

Rovi #2: Federal Court of Appeal Confirms Interactive Television Program Guide Patents Are Invalid (Rovi ats. Bell and Telus) Read More »

Rovi #1: Federal Court of Appeal Confirms Interactive Television Program Guide Patents Are Invalid (Rovi ats. Videotron)

  On August 6, 2024, the Federal Court of Appeal (per Gleason JA; Stratas and Monaghan JJA, concurring) held that two patents owned by Rovi Guides [Rovi] were invalid for obviousness. Nonetheless, in obiter, the FCA held that the trial judge erred in several aspects of his remedial analysis, including the correct approach for deciding

Rovi #1: Federal Court of Appeal Confirms Interactive Television Program Guide Patents Are Invalid (Rovi ats. Videotron) Read More »

FCA holds that Anticipation by Publication is a Difficult Defence to Establish

On August 19, 2024, the Federal Court of Appeal (per Locke JA; Woods and Laskin JJ.A., concurring) held that a patent claiming a specific herbicide (flucarbazone sodium) for the selective control of wild oats was not anticipated by two prior patents disclosing genera of herbicides for a variety of uses. Agracity Crop v. Upl Na

FCA holds that Anticipation by Publication is a Difficult Defence to Establish Read More »

Federal Court finds Jamp’s nintedanib capsules to infringe Boehringer’s use patent but not its formulation patent

On August 8, 2024, the Federal Court (per Furlanetto J.) held that a patent directed to nintedanib for use in the prevention or treatment of idiopathic pulmonary fibrosis (“IPF”) was valid and infringed, while a patent directed to formulations of nintedanib was not infringed.  Boehringer Ingelheim (Canada) Ltd. et al v. Jamp Pharma Corporation, 2024

Federal Court finds Jamp’s nintedanib capsules to infringe Boehringer’s use patent but not its formulation patent Read More »

Patent for Agricultural Computer System Held Invalid for Anticipation and Obviousness

On June 18, 2024, the Federal Court (per McHaffie J.) held that a patent for a computer system used to collect and process agricultural data was invalid for anticipation and obviousness.  Agi Suretrack, LLC v. Farmers Edge Inc., 2024 FC 934 Background Canadian Patent No 2,888,742 (the “742 Patent”) entitled “Farming Data Collection and Exchange

Patent for Agricultural Computer System Held Invalid for Anticipation and Obviousness Read More »